Non-Selective PDE4 Inhibition Induces a Rapid and Transient Decrease of Serum Potassium in Mice.

Area of Science:

• Pharmacology
• Biochemistry
• Physiology

Background:

• Phosphodiesterase 4 (PDE4) inhibitors are known for various therapeutic effects.
• Unexpectedly, Roflumilast, a PDE4 inhibitor, was observed to reduce serum potassium levels in mice.
• The mechanism behind this hypokalemic effect was not previously understood.

Purpose of the Study:

• To investigate the effect of PDE4 inhibitors on serum potassium levels.
• To determine if the observed hypokalemia is a class-characteristic property of PDE4 inhibitors.
• To elucidate the mechanism underlying PDE4 inhibitor-induced hypokalemia.

Main Methods:

• Administration of various PAN-PDE4 inhibitors (Roflumilast, Rolipram, RS25344, YM976) to mice.
• Measurement of serum potassium, sodium, and chloride levels.
• Assessment of hypothermia and hypokinesia.
• Evaluation of PDE4 inhibitor effects under anesthesia and in the presence of adrenergic agents (Isoprenaline, Yohimbine, Propranolol).

Main Results:

• Multiple PDE4 inhibitors dose-dependently reduced serum potassium, confirming a class effect.
• Hypokalemia occurred rapidly (within 15 min) and independently of hypothermia or hypokinesia.
• The effect was linked to modulation of adrenergic regulation of cellular potassium uptake, as evidenced by interactions with Isoprenaline, Yohimbine, and Propranolol.

Conclusions:

• PDE4 inhibitors induce hypokalemia through a mechanism independent of hypothermia and hypokinesia.
• The hypokalemic effect is mediated by modulating the adrenergic regulation of cellular potassium uptake.
• These findings reveal a novel physiological effect of PDE4 inhibition with potential clinical implications.